Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial

Nature Medicine

Volumn 6, Issue 10, 2000, Pages 1176-1182

  Kappos, Ludwig ^a,i   Comi, Giancarlo ^b,i   Panitch, Hillel ^c,i   Oger, Joel ^a,d,i,j   Antel, Jack ^e,f   Conlon, Paul ^g   Steinman, Lawrence ^h   Rae Grant, Alexander ^i,k   Castaldo, John ^i,l   Eckert, Nancy ^i,l   Guarnaccia, Joseph B ^i,l   Mills, Pamela ^i,m   Johnson, Gary ^i,m   Calabresi, Peter A ^i,m   Pozzilli, Carlo ^i,n   Bastianello, Stefano ^i,n   Giugni, Elisabetta ^i,n   Witjas, Tatiana ^i,o   Cozzone, Patrick ^i,o   Pelletier, Jean ^i,o   Pöhlau, Dieter ^i,p   Przuntek, Horst ^i,p   Hoffmann, Volker ^i,p   Bever Jr , Christopher ^c,i   Katz, Eleanor ^c,i   Clanet, Michel ^i,q   Berry, Isabelle ^i,q   Brassat, David ^i,q   Brunet, Irene ^i,r   Edan, Gilles ^i,r   Duquette, Pierre ^i,s   Radue, Ernst Wilhelm ^a,i   Schött, Dagmar ^a,i   Lienert, Carmen ^a,i   Taksaoui, Alice ^a,i   Rodegher, M ^b,i   Filippi, M ^b,i   Evans, Alan ^i,t   Bourgouin, Pierre ^i,t   Zijdenbos, Alex ^i,t   Salem, Shawki ^i,u   Ling, Nicholas ^g,i   Alleva, David ^g,i   Johnson, Eric ^g,i   Gaur, Amitabh ^g,i   Crowe, Paul ^g,i   Liu, Xin Jun ^g,i   more..

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f MCGILL UNIVERSITY   (Canada)

^g NEUROCRINE BIOSCIENCES INC   (United States)

^h STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Relapsing MS Study Group

^j Leigh Valley Hospital ^*

^k Leigh Valley Hospital   (United States)

^l Yale MS Clinic   (United States)

^m BROWN UNIVERSITY   (United States)

ⁿ SAPIENZA UNIVERSITY OF ROME   (Italy)

^o TIMONE HOSPITAL   (France)

^p ST JOSEF HOSPITAL   (Germany)

^q TOULOUSE UNIVERSITY HOSPITAL   (France)

^r PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^s UNIVERSITÉ DE MONTRÉAL   (Canada)

^t MCGILL UNIVERSITY   (Canada)

^u Symbiance Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; LIGAND; MYELIN BASIC PROTEIN; PLACEBO; TIPLIMOTIDE; UNCLASSIFIED DRUG;

ADULT; ALLERGIC ENCEPHALOMYELITIS; AMINO ACID SEQUENCE; ARTICLE; AUTOIMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS REACTION; DATA ANALYSIS; DEMOGRAPHY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; HELPER CELL; HUMAN; HYPERSENSITIVITY REACTION; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNE RESPONSE; INJECTION SITE; LIGAND BINDING; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE;

EID: 0033791462     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/80525     Document Type: Article

References (41)

1. Immunological aspects of demyelinating diseases
2. Multiple sclerosis: A coordinated immunological attack against myelin in the central nervous system
3. Progress in determining the causes and treatment of multiple sclerosis
4. A full genome search in multiple sclerosis
5. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22
6. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatibility complex
7. Visualization of myelin basic protein [MBP] T cell epitopes in MS lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen HLA DR2 MBP 95-99 complex
8. Selection for T cell receptor Vb-Db-Jb gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis
9. T cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis
10. A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis
11. Major T cell responses in multiple sclerosis
12. Separation of T helper 1 clone cytolysis from proliferation and lymphokine production using analog peptides
13. A single TCR antagonist peptide inhibits experimental autoimmune encephalomyelitis mediated by a diverse T cell repertoire
14. Relationships among TCR ligand potency, thresholds for effector function elicitation, and the quality of early signaling events in human T cells
15. Reversal of experimental autoimmune encephalomyelitis by a soluble variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of Interferon-γ and TNF-α production
16. Amelioration of relapsing experimental autoimmune encephalomyelitis with altered myelin basic protein peptides involves different cellular mechanisms
17. Double-blind randomized placebo control parallel-group evaluation of the safety and effect on immunological parameters of the altered peptide ligand MSP771 in patients with MS
18. Preferential expansion of autoreactive T lymphocytes from the memory T-cell pool by IL-7
19. Analysis of an IFN-gamma gene (IFN-γ) polymorphism in multiple sclerosis in Europe: Effect of population structure on association with disease
20. Immunological therapy of MS
21. Escape from horror autotoxicus: The pathogenesis and treatment of autoimmmunity
22. Viral damage and the breakdown of self-tolerance
23. Treatment of MS with gamma interferon: Exacerbations associated with activation of the immune system
24. Cytokine profile of MBP-reactive T cells in MS and healthy individuals
25. Augmented expression of TNFα and lymphotoxin in mononuclear cells in multiple sclerosis and optic neuritis
26. TNF identified in MS brain
27. The adhesion molecule and cytokine profile of MS lesions
28. Multiple sclerosis: Involvement of interferons in lesion pathogenesis
29. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis
30. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein
31. A predictable sequential determinant-spreading cascade invariably accompanies progression of EAE: A basis for peptide-specific therapy after onset of clinical disease
32. Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand
33. Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients
34. The effect of Copaxone® on disease activity as measured by cerebral MRI in patients with RRMS: A multi-center, randomized double blind, placebo controlled study extended by open label treatment
35. Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking
36. Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis
37. Treatment of multiple sclerosis with T-cell receptor peptides: Results of a double-blind pilot trial
38. Preferential TCR beta chain variable gene use in MBP reactive T cell clones from patients with MS
39. Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space